(Total Views: 410)
Posted On: 12/18/2019 3:23:23 PM
Post# of 153998
BREAKING NEWS: CytoDyn (OTC: CYDY) jumps +42% on HIV drug licensing deal. CYDY is latest WINNER to emerge from NEXT SUPER STOCK Conference
Wed, Dec 18, 2019 2:57 pm
News Desk - Wall Street Reporter (jm@wallstreetreporter.com)
To:you Details
December 18, 2019
NEWSMAKERS
The latest news updates from NEXT SUPER STOCK Conference presenters....
Nader Purhassan, Ph.D. CEO CytoDyn, Inc.
BREAKING NEWS:
NEXT SUPER STOCK conference presenter, CytoDyn (OTC: CYDY) rockets +42% higher today on licensing deal to commercialize Leronlimab in the U.S. for the Treatment of HIV
VANCOUVER, Washington and NEW YORK, Dec. 17, 2019 -- CytoDyn Inc. (OTC QB: CYDY), ("CytoDyn"
and Vyera Pharmaceuticals, LLC ("Vyera", today announced that they have entered into a Commercialization and License Agreement (CLA) and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV.
Under the terms of the CLA, CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Vyera has been granted an exclusive license to market and distribute leronlimab in the U.S. for the treatment of HIV. In exchange for such exclusive license, Vyera has agreed to pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera also agreed to make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock. CLICK HERE FOR FULL STORY
Click here to watch CytoDyn's presentation at Wall Street Reporter's NEXT SUPER STOCK Conference 11/14/2019
Wed, Dec 18, 2019 2:57 pm
News Desk - Wall Street Reporter (jm@wallstreetreporter.com)
To:you Details
December 18, 2019
NEWSMAKERS
The latest news updates from NEXT SUPER STOCK Conference presenters....
Nader Purhassan, Ph.D. CEO CytoDyn, Inc.
BREAKING NEWS:
NEXT SUPER STOCK conference presenter, CytoDyn (OTC: CYDY) rockets +42% higher today on licensing deal to commercialize Leronlimab in the U.S. for the Treatment of HIV
VANCOUVER, Washington and NEW YORK, Dec. 17, 2019 -- CytoDyn Inc. (OTC QB: CYDY), ("CytoDyn"
and Vyera Pharmaceuticals, LLC ("Vyera", today announced that they have entered into a Commercialization and License Agreement (CLA) and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV. Under the terms of the CLA, CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Vyera has been granted an exclusive license to market and distribute leronlimab in the U.S. for the treatment of HIV. In exchange for such exclusive license, Vyera has agreed to pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera also agreed to make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock. CLICK HERE FOR FULL STORY
Click here to watch CytoDyn's presentation at Wall Street Reporter's NEXT SUPER STOCK Conference 11/14/2019
(2)
(0)
